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ABSTRACT

C-REACTIVE PROTEIN LEVELS ACCORDING TO PHYSICAL ACTIVITY
AND BODY WEIGHT FOR PARTICIPANTS IN THE CORONARY
HEALTH IMPROVEMENT PROJECT

Michael T. Massey
Department of Exercise Sciences
Master of Science

Objectives. To evaluate C-reactive protein (CRP) levels according to weight and physical
activity. The study explored how changes in CRP were associated with baseline CRP,
weight, and physical activity and changes in these variables.
Methods. A randomized controlled study design assigned 348 individuals to the
intervention or control group with measurements taken at baseline, 6 weeks, and 6
months of body weight, physical activity, and serum CRP levels. Participants attended an
intensive 40-hour educational course delivered over a four-week period.
Results. At baseline, CRP was negatively associated with total steps/week, and positively
associated with weight, BMI, percent fat, and saturated fat at baseline. CRP significantly
decreased through 6 weeks and also through 6 months for only those with high CRP at
baseline. For those with high CRP at baseline, the decrease was significant for normal,

overweight, and obese groups of people, albeit most pronounced for those with normal
weight at baseline and least pronounced for those who were obese at baseline. Changes in
weight or physical activity were not significantly associated with changes in CRP.
Conclusions. Over 6 week and 6 month follow-up periods, the intervention failed to
discriminate changes in CRP. Changes in CRP were only associated with baseline levels
of CRP and BMI and were not associated with changes in any of the selected variables
considered.
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ABSTRACT
Objectives. Evaluate C-reactive protein (CRP) levels according to weight and physical
activity. The study explored how changes in CRP were associated with baseline CRP,
weight, and physical activity and changes in these variables.
Methods. A randomized controlled study design assigned 348 individuals to the
intervention or control group with measurements taken at baseline, 6 weeks, and 6
months of body weight, physical activity, and serum CRP levels. Participants attended an
intensive 40-hour educational course delivered over a four-week period.
Results. At baseline, CRP was negatively associated with total steps/week, and positively
associated with weight, BMI, percent fat, and saturated fat at baseline. CRP significantly
decreased through 6 weeks and also through 6 months for only those with high CRP at
baseline. For those with high CRP at baseline, the decrease was significant for normal,
overweight, and obese groups of people. Changes in weight or physical activity were not
significantly associated with changes in CRP.
Conclusions. Over 6 week and 6 month follow-up periods, the intervention failed to
discriminate changes in CRP. Changes in CRP were only associated with baseline levels
of CRP and BMI and were not associated with changes in any of the selected variables
considered.
Keywords: C-reactive protein (CRP); physical activity; body weight; percent body fat;
saturated fat; body mass index (BMI); Coronary Health Improvement Project (CHIP)
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INTRODUCTION
C-reactive protein (CRP) is a nonspecific acute-phase reactant that has
traditionally been used to detect acute injury infection and inflammation (Backes, et al.,
2004). Some of the typical causes of inflammation are cytomegalovirus, chlamydia
pneumoniae, dyslipidemia, obesity and/or hormone replacement therapy (Sobal and
Sinzinger, 2005). Recent studies have shown a positive independent association between
CRP and atherosclerotic events (Backes, et al., 2004, Kasapis and Thompson, 2005,
Ledue and Rifai, 2003). It has also been shown that high CRP is a significant and
independent risk predictor of nontraumatic bone fractures (Schett, et al., 2006).
The level of serum CRP in the plasma indicates the severity of inflammation
(Coppola, et al., 2006). Studies have determined that CRP levels above 3 mg/L are a good
prognostic marker for future vascular events. People with and without cardiovascular
arterial disease (CAD) with CRP levels above 3 mg/L are at significantly greater risk of
ischemic episodes than those with CRP below 3 mg/L (Backes, et al., 2004, Coppola, et
al., 2006). Serum CRP levels from 1-3 mg/L and below 1 mg/L have been shown to be at
normal and low risk for CAD, respectively. Further research is needed to develop
standard CRP prognostic markers for nontraumatic bone fractures.
CRP levels can be lowered through drug therapy (Sobal and Sinzinger, 2005).
There is also evidence that a lifestyle intervention that improves a person's physical
activity and/or eating habits may reduce CRP (Caulin-Glaser, et al., 2005, Blum, et al.,
2006). Reduction of CRP levels through physical activity and weight loss is a practical
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way of reducing the likelihood of a cardiac event. The Coronary Health Improvement
Project (CHIP) is a specific lifestyle intervention program that may positively impact
CRP levels. It is a 4-week health education intervention program that teaches participants
how to improve their eating habits and physical activity in order to benefit their cardiac
health. It is assumed that the program will reduce CAD risk factors, including CRP
levels.
This study evaluated CRP levels according to weight and physical activity. It also
explored how changes in CRP are associated with baseline CRP, weight, and physical
activity and changes in these variables.
METHODS
Subject Recruitment
The SwedishAmerican Center for Complementary Medicine (SACCM) recruited
participants for this study. Recruitment was from the Rockford, IL, metropolitan area
with the requirement that participants be 18 years of age or older. All participants
provided informed consent. Many enrolled with a spouse or significant other. For those
who participated in the program with their partner (42%), the unit of randomization was
pairs. For those who participated as individuals (58%), the unit of randomization was
individuals. No significant differences were observed between pairs and individuals.
Randomization was determined by a random number generator. The study coordinator
conducted the participant sign-up process, randomization, and group assignments.
Participants were excluded from the study if they had a significant condition or major
illness that would prevent them from exercising. There were 403 individuals assessed for
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eligibility. Three-hundred and seventy-seven were eligible, but 29 refused to participate,
leaving 348 who were randomly assigned to start the program immediately (intervention
group) or to wait for 6 months before beginning the program (control group). None of the
participants were lost to follow-up throughout the 6 month period. The Institutional
Review Board of the SwedishAmerican Health System approved the study on August 29,
2002.
Design
The study was a randomized study involving intervention and control groups.
Measurements were taken at baseline, 6 weeks, and 6 months. The health education
intervention was received during the first 4 weeks. The control group received no
intervention during the 6 month follow-up period and was specifically told not to alter
their lifestyle during the investigative period.
Intervention
The CHIP (Diehl, 1998) is an intensive community-based education intervention.
Participants are required to attend a 4-week class. Each class is 2 hours long and there are
4 classes per week. Total class time is approximately 32 hours. Theory-based intervention
planning was used to develop the curriculum, class design, alumni association, and each
of the take-home assignments (Lupton, et al., 2003, Tudor-Locke, et al., 2004, Toobert, et
al., 2003). The intervention incorporated learning theory (behaviorism) in which changes
in physical and dietary behaviors were promoted using health education and positive
reinforcement. In addition to encouragement and positive feedback from staff, the CHIP
alumni program was designed to help participants maintain positive behavior changes.
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The curriculum included the following topics: modern medicine and health myths,
atherosclerosis, coronary risk factors, obesity, dietary fiber, dietary fat, diabetes,
hypertension, cholesterol, physical activity, osteoporosis, cancer, lifestyle and health, the
Optimal Diet, behavioral change, and self-worth.
The intervention group received a textbook and workbooks in conjunction with
the CHIP lectures that closely followed the discussion topics and contained assignments
with learning objectives that correlated with the discussion topics. These assignments
were designed to assist the intervention group in understanding and integrating the
concepts and information presented into their lives. Dieticians and medical professionals
introduced the intervention group to current nutritional and medical information that
related to the prevention of chronic diseases weekly.
The intervention group made dietary and physical activity goals, which they were
encouraged to then follow. The dietary goal involved adopting a more plant-food based
diet that emphasizes "as-grown," unrefined food. Prescribed foods included whole grains,
legumes, vegetables, and fresh fruits. The diet was low in fat, animal protein, sugar, salt,
very low in cholesterol, and high in fiber. The intervention group was also, accordingly
with their new diet, encouraged to progressively work toward walking or exercising at a
mild-to-moderate intensity for at least 30 minutes a day. A pedometer was given to the
intervention group and they were encouraged to keep a physical activity log that recorded
the miles they walked each day.
The primary objective of the health education intervention was to improve
cognitive understanding of the importance of healthy lifestyles, nutrition and physical
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activity behavior, risk factors associated with diabetes, hypertension, cardiovascular
disease, and cancer.
Measures
A number of variables were considered to evaluate cardiovascular risk factors and
individual health variation among participants. Measures included pedometer readings
(step counts), CRP levels, body fat percentage, saturated fat levels, weight, height, BMI,
chronic inflammatory conditions, age, and gender.
To determine the level of physical activity, a 7-day self-recorded pedometer log
was maintained by each participant a week before measurements at baseline, 6 weeks,
and 6 months. Participants from the intervention and control group wore the Walk4Life
Model 2000 Life Stepper pedometer on a belt at the right hip directly above the right
knee cap each day for 7 consecutive days. Immediately prior to going to bed the
pedometer counts for the day were recorded and the number reset. Strike counts from
pedometers are a valid and reliable method of monitoring and measuring free-living
physical activity (Crouter, et al., 2003, Beets, et al., 2005, Tudor-Locke, et al., 2005).
Crouter et al. (Crouter, et al., 2003) determined the validity of the Walk4Life Life
Stepper pedometer by comparing pedometer readings with the number of actual steps of
participants walking for 5 min on a treadmill at various speeds (54, 67, 80, 94, and 107
m/min). The correlation coefficient was (r = 0.81, p < 0.05) which Crouter indicates is
acceptable to ascertain physical activity and “a good choice to use in research.” Beets et
al. (Beets, et al., 2005) also assessed the Walk4Life pedometer by comparing it to actual
steps from self-paced walking and treadmill walking (speeds: 40, 54, 67, 80, and 94
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m/min). The intraclass correlation coefficient was (R = 0.997) for self-paced walking and
(R = 0.516, 0.745, 0.946, 0.988 and 0.992) (p < 0.05) for treadmill speeds 40, 54, 67,
80, and 94 m/min respectively. Beets and Crouter both mention the Walk4Life pedometer
to be more accurate the faster one walks.
Tudor-Locke et al. (Tudor-Locke, et al., 2005) conducted a study to determine
how many days of pedometer readings are needed to determine the weekly physical
activity of an adult. There were 90 participants enrolled (33 men and 57 female aged
49 +/-16.2 years and 44.8 +/-16.9 years respectively). BMI ranged from 21.1 to 33.9
kg/m2. There was an R2 of 0.94 and an intraclass correlation of 0.80 for wearing the
pedometer for three days. The conclusion was that the time necessary to determine
physical activity in a week with a pedometer was 3 days. Thus, the time taken from this
study (7 days) to determine physical activity was sufficient.
Phlebotomists from the SwedishAmerican Health System's outpatient laboratory
drew blood using a vacutainer (Becton-Dickinson Vacutainer Systems, Rutherford, NJ)
after the participants had a 12-hour fast. Samples were allowed to clot and then
centrifuged. Clinical analyses were completed at the SwedishAmerican Health System
laboratory. CRP was determined using a microplate protocol based on a latex bead
enhanced immunoturbidity assay from the same technician and has been demonstrated to
be a valid and reliable method (Wu, et al., 2002, Otsuji, et al., 1982, Rifai, et al., 1999).
Otsuji et al. (Otsuji, et al., 1982) conducted a study that demonstrates a turbidimetric
immunoassay method for determining serum CRP that can be used with any
spectrophotometer that can measure turbidimetrically at 340 nm. The measured
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absorbances of a test sample (50 μL of serum + 2.0 mL of working antiserum solution),
sample blank (50 μL of serum + 2.0 mL of sample blank buffer), reagent blank (50 μL of
saline + 2.0 mL of working antiserum solution), and buffer blank (50 μL of saline + 2.0
mL of sample blank buffer) were prepared and incubated at 37 °C for 30 min.
Absorbances for the test sample (AS), sample blank (ASB), the reagent blank (ARB), and
the buffer blank (ABB) were measured. The CRP absorbance (ACRP) indicating serum
CRP was calculated by the following equation: ACRP = AS – ASB – (ARB – ABB). It was
indicated that precision was good due to low CV% and SD at various CRP
concentrations.
Rifai et al. (Rifai, et al., 1999) compared latex-enhanced immunoassay for hsCRP with Enzyme-Linked ImmunoSorbent Assay (ELISA), a previously validated
method for measuring hs-CRP, (Wu, et al., 2002) in a case controlled study using patients
with peripheral arterial disease. There were 288 subjects (144 case subjects and 144
control subjects) enrolled. The Latex assay used monoclonal anti-CRP antibodies coated
to polystyrene particles that formed a complex with hs-CRP present in the measured
study sample. The amount of scattered light was directly proportional to the size of the
antigen-antibody complex and reflected the hs-CRP concentration present in the study
sample. The run-to-run CVs, at hs-CRP concentrations of 0.47, 10.5, and 54.9 mg/L were
6.4%, 3.7%, and 2.9%, respectively. The correlation between the Latex and ELISA
methods based on original and log-normalized data were (r = 0.95, p < 0.001) and
(r = 0.93, p < 0.001) respectively for both case and control groups. Thus, Rifai concluded
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that the Latex method was comparable to ELISA and can be used in research to
determine CRP levels.
Percent body fat was estimated using the Tanita TBF - 300A electrical impedance
scale, which has been shown to be a valid and reliable method (Kyle, et al., 2001,
Rubiano, et al., 2000). Kyle et al. (Kyle, et al., 2001) developed a study to validate a
single bioelectrical impedance analysis (BIA) equation for 343 healthy white subjects
(202 men and 141 women) aged 22-94 with a BMI between 17.0 and 33.8 kg/m. Fat-free
mass (FFM) was measured by dual-energy x-ray absorptiometry (DEXA) (Hologic QDR4500) and BIA (Xitron 4000B). Significant correlations were high (r = 0.986-0.987,
p < 0.05), the standard error for the estimates was low (SEE = 1.72 kg), and technical
error was 1.74 kg. A valid single prediction for FFM was developed: FFM = -4.104 +
(0.518 x height(m)(2)/resistance (kg)) + (0.231 x weight (kg)) + (0.130 x reactance
(ohm)) + (4.229 x sex: men = 1, women = 0). He concluded that the single prediction
equation was valid for prediction of FFM in populations with large variations of age and
body composition.
Rubiano et al. (Rubiano, et al., 2000) investigated the validity of the leg-to-leg
BIA (Tanita TBF 310) to measure body composition using DEXA as a reference. He
enrolled 39 subjects (8 male and 31 female) aged from 37 to 73 years of age with a BMI
from 24.6 to 32.6. A significantly high correlation was observed (r = 0.94, p < 0.001,
SEE = 3.6 percent body fat) for measuring body fat percentage. Rubiano concludes that
leg-to-leg BIA systems may be useful in assessing total body composition in a population
varying in BMI.
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Saturated fat was estimated by the participants completing a self administered
food survey based on the 98 item Block questionnaire (Block, et al., 1990, Hartman, et
al., 1996). Block et al. (Block, et al., 1990) determined this type of questionnaire to be a
valid method for determining saturated fat intake. Hartman et al. (Hartman, et al., 1996)
determined the reliability of this questionnaire to be adequate for research purposes. They
reported intraclass correlations between three administrations of the same survey during
three different seasons between 0.56 and 0.82.
Weight and height were measured using standard medical weight and height
scales calibrated by the Biometrics Department of the SwedishAmerican Health System.
Body mass index (BMI) was determined using the formula weight (kg)/height (m)2.
Presence of chronic inflammatory conditions were determined by health history
questionnaire and documented by medical staff. Age and gender were also ascertained.
Statistical Analyses
Frequency distributions were computed and cross-tabulations were used to
perform bivariate analyses between intervention status (intervention vs. control) and
selected demographic variables and medication use, with statistical significance based on
the Chi-square test (χ2) (Fienberg, 1977). The Pearson correlation coefficient (r) was used
to assess associations between selected variables at baseline. Comparisons between
means were made and multiple regression analysis was used to assess the simultaneous
influence of selected variables on CRP. The F- and t-statistics were used to evaluate
regression models and measures of association. Analyses were performed using SAS
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version 9.1 (SAS Institute Inc., Cary, NC, USA, 2003). Statistical significance and
confidence intervals were based on the 0.05 level.
RESULTS
Of the 348 participants, ages ranged from 24 to 81 years (M = 50.4, SD = 11.0).
The mean age for the intervention group was 50.1 years compared with 50.8 years in the
control group [t(346)= −0.57, p =0 .57]. Characteristics of the study participants are
presented for selected demographic variables in Table 1. Distributions across the levels of
each variable were not significantly different between the intervention and control
groups. The most common characteristic observed for each variable was: female; white;
married; an annual family income of at least $60,000; and at least some college
education.
At baseline, there were significant correlations between CRP and total steps/week
(r = -0.23, p < 0.0001), weight (r = 0.46, p < 0.0001), BMI (r = 0.54, p < 0.0001), percent
fat (r = 0.12, p = 0.0258), and saturated fat (r = 0.13, p = 0.0158). Improvements in total
steps/week, weight, BMI, percent fat, and saturated fat were observed, and were
significantly greater for those in the intervention group compared with the control group
(Table 2). There was not a significant difference in change in C-reactive protein (CRP)
between intervention and control groups.
C-reactive protein was categorized into low, normal, and high groups (Table 3).
C-reactive protein tended to increase for those with low or normal CRP at baseline, albeit
only significantly so through 6 weeks for those with low CRP at baseline. On the other
hand, CRP significantly decreased through 6 weeks and 6 months for those with high
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CRP at baseline. The level of CRP did not significantly differ between the intervention
and control groups across the baseline levels of CRP.
C-reactive protein at 6 weeks was regressed on those variables shown in Table 2.
Using backward elimination, baseline BMI (t = 5.83, p < 0.0001) and baseline CRP
(t = 11.21, p < 0.0001) were the only variables that remained significant in the model.
The same was true for the model involving CRP at 6 months (i.e., t = 6.61, p < 0.0001 for
baseline BMI and t = 10.31, p < 0.0001 for baseline CRP).
Mean change in CRP through 6 weeks and 6 months is presented according to
categories of CRP and BMI at baseline in Table 4. We collapsed over intervention and
control groups because no difference was observed in changes in CRP between these
groups. For low CRP at baseline, changes in CRP were greater with higher BMI at
baseline. The increase observed earlier for those with low CRP at baseline was greatest
among individuals who were obese. On the other hand, the decrease observed for those
with high CRP at baseline was greatest among those who are of normal weight.
DISCUSSION
At baseline, serum CRP levels were significantly associated with total steps/week,
weight, BMI, percent fat, and saturated fat. However, although the intervention resulted
in significant improvements in total steps/week, body weight, BMI, percent fat, and
saturated fat among participants in the intervention group, there was no significant
improvement observed in CRP levels. However, by stratifying according to baseline
CRP, those with high CRP at baseline showed a significant decrease over the study
period. CRP levels at 6 weeks and again at 6 months were significantly associated with
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baseline BMI and baseline CRP. For those with low CRP at baseline, a significant
positive change was observed through 6 weeks and 6 months. For those with high CRP at
baseline, a significant decrease was observed in CRP through 6 weeks and 6 months. The
decrease was most pronounced for those of normal weight and least pronounced for those
who are obese. The intervention did not discriminate these patterns.
Excess adipose increases inflammation and expression of CRP (Anty, et al.,
2006). The lifestyle changes of exercise and nutrition, as implemented by the CHIP,
should have the greatest affect on individuals that are sedentary and obese. Typically
these attributes, particularly obesity, are altered significantly through positive lifestyle
changes of physical activity and nutrition. BMI, in a normal population, often has a
positive association with individual CRP levels due to its association with adiposity. The
majority of individuals who were obese, as indicated by their BMI, had high levels of
CRP at baseline. These individuals significantly lowered their baseline CRP levels as the
trial progressed. This occurred, most likely, in response to improvements in dietary
intake. It should be noted that the overweight and normal weight individuals with high
CRP levels experienced a greater reduction of CRP, normal weight achieving the greatest
reduction, than the obese individuals as the trial progressed. A possible explanation for
this occurrence is that obese individuals are not as likely to maintain improvements in
their exercise and eating habits as are people with lower weight.
Individuals with low CRP levels, according to BMI at baseline, increased their
mean CRP levels as the study progressed. There is nothing in the current literature that
would indicate that the CHIP intervention would raise CRP levels for individuals who
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have low CRP at baseline. Obese individuals with low CRP levels at baseline increased
their CRP levels more so than those with low CRP at baseline who were of normal
weight or overweight. The reason for this result is unclear, and deserves further study.
The intervention group’s physical activity increased during the six month trial,
from 40,579 steps per week (5,797 steps per day) to 47,290 steps per week (6,756 steps
per day), after controlling for extra steps from the control group. Tudor-Locke et al.
(Tudor-Locke and Bassett, 2004) indicate that these pedometer readings would rank the
intervention group in a “low active” category. This was not enough physical activity to
determine a significant independent correlation of physical activity with CRP. However,
despite the low physical activity reported by the intervention group, it should be noted
that they increased their physical activity significantly, by 30.5%. Hence, overall the
efficacy of the CHIP intervention was demonstrated for improving physical activity and
lowering weight, but not for CRP.
The participants in this study were mostly white and sufficiently self-motivated to
volunteer to participate in the study. On average, participants were slightly more educated
than the community average. Participants had lifestyles that permitted them to attend
most, if not all, of the classes. This is evident in the high rate of attendance to this timeintensive program. Hence, generalization of these findings should be done with caution.
Because the participants were self-selected, the results from this intervention may
represent a best-case scenario.
The study is limited by the fact that physical activity, weight, and nutrition data
were self-reported. For some variables, the control group also experienced significant
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improvement, as seen with decreases in CRP among those with high CRP at baseline.
Interviews with control group participants revealed that some participants were anxious
to get started on improving their health behaviors, and may have begun prior to starting
CHIP six months after the intervention group.
CONCLUSION
CRP was negatively associated with total steps/week, and positively associated
with weight, BMI, percent fat, and saturated fat at baseline. However, CRP at 6 weeks
and again at 6 months was only associated with baseline BMI and CRP. Participants with
high levels of CRP at baseline who were obese showed a significant reduction of CRP
over the course of the study. This is consistent with the literature, as a reduction in
adiposity would reduce inflammation and CRP levels. A longer trial and improvements in
the methods for measuring CRP data should be included in further such studies for better
understanding the relationships between changes in CRP levels and changes in physical
activity and changes in body weight.
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Table 1: Comparison of Demographic Characteristics of Intervention and Control
Groups in a Therapeutic Lifestyle-Modification Program, Rockford, Illinois
Intervention
Demographic Characteristic
Sex

χ2df (P)

Control

No.

%

No.

%

47

27.0

51

29.3

127

73.0

123

70.7

Race
White
Black

167
4

96.0
2.3

160
10

93.0
5.8

Other

3

1.7

2

1.2

12

6.9

20

11.6

138
16
7

79.8
9.2
4.1

127
16
10

73.4
9.2
5.8

$0– <$20,000

14

8.2

12

7.1

$20,000– <$40,000

34

20.0

28

16.5

$40,000– <$60,000
$60,000 +

37
85

21.8
50.0

41
89

24.1
52.3

4

2.3

7

4.0

37
58
39
34

21.5
33.7
22.7
19.8

46
39
38
43

26.6
22.5
22.0
24.9

Male
Female

Marital Status
Never married
Married
Divorced
Widowed
Annual family income, $

Education
<High school
High school
Some college
Bachelor degree
Post-bachelor degree

0.23, 1
(0.63)

2.91, 2
(0.23)

2.99, 3
(0.39)

1.03, 3
(0.79)

6.58, 4
(0.16)
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Table 2: Physical activity and other selected variables at baseline and 6-month follow-up among participants in a therapeutic
lifestyle-modification program, Rockford, Illinois
No.

Baseline
Mean

6 Week
Mean

Difference
In Mean
between
Baseline
and 6
Weeks

95% CI

6 Month
Mean

Difference
In Mean
between
Baseline
and 6
Months

95% CI

173
173

40,579
43,869

52,429
45,825

11,656
2,105*

9,122, 14,190
-277, 4,487

52,951
49,530

12,476
5,315*

9,773, 15,179
2,769, 7,862

174
174

33.3
31.4

32.1
31.3

-1.2
-0.1*

-1.3, -1.1
-0.2, -0.0

31.7
31.1

-1.6
-0.3*

-1.9, -1.3
-0.5, -0.1

174
174

93.3
87.7

90.0
87.6

-3.3
-0.1*

-3.6, -3.0
-0.7, 0.4

88.8
87.1

-4.5
-0.6*

-5.3, -3.8
-1.5, 0.1

173
174

36.7
34.6

28.0
34.1

-8.7
-0.5*

-10.3, -7.4
-1.4, 0.2

28.5
35.5

-8.2
0.9*

-9.3, -7.0
-0.0, 1.9

173
174

26.3
21.8

15.0
19.2

-11.3
-2.6*

-13.7, -9.2
-3.7, -1.4

13.3
20.5

-13.0
-1.3*

-14.9, -11.0
-2.6, -0.1

168
167

4.2
3.8

3.9
3.7

-0.3
0.1

-0.7, 0.2
-0.5, 0.5

3.8
3.6

-0.4
-0.1

-0.9, 0.1
-0.6, 0.4

Variable

Total steps/week
Intervention
Control
Body mass index
Intervention
Control
Weight, kg
Intervention
Control
Body fat, %
Intervention
Control
Saturated fat, g
Intervention
Control
C-reactive protein, mg/L
Intervention
Control
*

Significant difference between intervention and control group’s mean difference scores from baseline through follow-up, p < 0.05.
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Table 3: C-reactive protein, mg/L, at baseline, 6 weeks and 6-month follow-up among participants in a therapeutic lifestylemodification program, Rockford, Illinois
No.

Baseline
Mean

28
38

0.6
0.6

1.5
1.5

0.9
0.9

0.1, 1.7
0.2, 1.7

1.4
1.2

0.8
0.6

-0.0, 1.7
-0.1, 1.3

60
55

1.8
1.8

2.4
2.5

0.6
0.7

-0.1, 1.1
-0.1, 1.5

2.2
2.3

0.4
0.5

-0.2, 1.0
-0.2, 1.2

80
74

7.1
6.8

5.8
5.8

-1.3
-1.0

-2.0, -0.6
-1.8, -0.2

5.7
5.8

-1.4
-1.0

-2.2, -0.6
-1.8, -0.1

CRP
Group
Low < 1
Intervention
Control
Normal 1 - 3
Intervention
Control
High > 3
Intervention
Control

6 Week Difference
Mean
In Mean
between
Baseline
and 6
Weeks

95% CI

6 Month Difference
Mean
In Mean
between
Baseline
and 6
Months

95% CI

Note: there was no difference between intervention and control groups at 6 weeks or 6 months after adjusting for baseline differences
in CRP.
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Table 4: Change in C-reactive protein, mg/L, through 6 weeks and 6 months according to CRP and BMI at baseline, among
participants in a therapeutic lifestyle-modification program, Rockford, Illinois

No.

C-Reactive
protein, mg/L
through 6 weeks
Mean Change

95% CI

C-Reactive
protein, mg/L
through 6 months
Mean Change

95% CI

32
22
12

0.47
0.41
3.08*

-0.03, 0.97
0.08, 0.76
0.49, 5.68

-0.77
0.60
2.98*

-0.25, 0.10
-0.21, 1.35
0.71, 5.25

19
43
53

0.76
0.07
0.95

-0.63, 2.15
-0.67, 0.82
0.22, 1.69

0.90
-0.25
0.79

-0.61, 2.40
-0.76, 0.26
0.03, 1.56

13
30
111

-3.48
-1.64
-0.71*

-5.86, -1.10
-2.92, -0.37
-1.28, -0.13

-3.08
-1.80
-0.78*

-5.90, -0.26
-3.12, -0.47
-1.42, -0.15

CRP
BMI
Low < 1
Normal (BMI < 25)
Overweight (25 ≤ BMI < 30)
Obese (BMI ≥ 30)
Medium 1 – 3
Normal (BMI < 25)
Overweight (25 ≤ BMI < 30)
Obese (BMI ≥ 30)
High > 3
Normal (BMI < 25)
Overweight (25 ≤ BMI < 30)
Obese (BMI ≥ 30)
*

Significant difference in changes in mean CRP levels across categories of BMI, p < 0.05.
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Chapter 1
Introduction
Atherosclerosis is the primary cause of coronary artery disease (CAD). It is an
inflammatory vascular disease that hardens the walls of medium and large arteries due to
the deposits of fatty-fibrous tissue (plaque) that develop from subendothelial
accumulation and is caused by lifestyle and genetic factors.[1] As plaque develops, blood
flow is restricted and ischemia results. Atherosclerosis occurs throughout the body and
takes decades to develop before a cardiac event (i.e. myocardial infarction, sudden death,
angina pectoris). Many risk factors are associated with the development of
atherosclerosis. Some of the traditional risk factors that can be manipulated through
lifestyle intervention include dyslipidemia, hypertension, smoking, diabetes, body mass
index (BMI) and high homocysteine levels.[2]
C-reactive protein (CRP) is a nonspecific acute-phase reactant that has
traditionally been used to detect acute injury infection and inflammation.[3] Some of the
typical causes of inflammation are cytomegalovirus, chlamydia pneumoniae,
dyslipidemia, obesity and/or hormone replacement therapy.[1] Several recent studies have
shown a strong independent association between CRP and atherosclerotic events.[3-5]
The level of CRP in the plasma indicates the severity of inflammation.[6] Studies
have determined that CRP levels above 3 mg/L are a good prognostic marker for future
vascular events. That is, people, with and without CAD, with levels above 3 mg/L will
likely have more ischemic episodes than those below 3 mg/L.[3, 6]
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CRP Levels can be lowered through drug therapy[1] and/or a lifestyle intervention
that improves a person's exercise and/or eating habits.[7, 8] Reduction of CRP levels
through exercise and weight loss is thought to be a practical way of ensuring a higher
quality of life by reducing the likelihood of a cardiac event. The Coronary Health
Improvement Project (CHIP) is a specific lifestyle intervention program that may
positively impact CRP levels. It is a 4-week lecture program with a curriculum that
teaches participants how to change their lifestyle habits to benefit their cardiac health
through proper eating habits and exercise. It is assumed that the program will reduce
CAD risk factors, including CRP levels.
Statement of the Problem
The literature on CRP describes different methods to lower its levels through
drugs and different lifestyle intervention programs. Currently there is not a program that
has been established to be the most efficacious in lowering CRP levels. The purpose of
this study is to determine the independent and interactive correlation of changes in
physical activity and weight with CRP levels. Participants in a CHIP group and control
group have been assessed at baseline, six weeks, and six months to determine the changes
in CRP levels that are associated with changes in body weight and/or exercise habits.
Research Questions
1. What is the independent correlation of changes in physical activity with CRP
levels for CHIP participants?
2. What is the independent correlation of changes in weight with CRP levels for
CHIP participants?
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3. What is the interactive correlation of changes in physical activity and weight with
CRP levels for CHIP participants?
4. What impact do medications, gender, body composition, chronic diseases, and
confounding variables have on the correlation of changes in physical activity and
weight with CRP levels for CHIP participants?
Assumptions
All participants self-reported answers to questions regarding nutrition and
exercise were reported truthfully.
Delimitations
Participants were only selected from the greater Rockford, IL, metropolitan area
and have very little minority representation.
Limitations
Participants are primarily from one area and are mostly white, which may affect
the generalization of the study.
Significance
The CHIP program was designed to improve a person's lifestyle habits related to
exercise and nutrition to reduce the likelihood of a cardiac event. Reducing CRP levels is
less understood than the reduction of other CAD risk factors. Currently there is not a
standard protocol to follow when a patient presents with high levels of CRP and other
risk factors that contribute to CAD. Lifestyle intervention (i.e. exercise and nutrition)
may be an efficient and practical way of lowering CRP levels to reduce the likelihood of
CAD.
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Chapter 2
Review of the Literature
C-reactive protein (CRP) is a nonspecific acute-phase reactant that has
traditionally been used to detect acute injury infection and inflammation.[3] It is
synthesized by hepatocytes and has an overall molecular weight of 11,800 Da. CRP
production is stimulated by cytokines upon inflammation and rapidly declines upon
inflammatory resolution. Despite these transient fluctuations, CRP levels remain
relatively constant in an individual.[9] Some of the possible causes of inflammation are
cytomegalovirus, chlamydia pneumoniae, dyslipidemia, obesity and/or hormone
replacement therapy. However, recent evidence suggests that CRP levels are a good
indicator of predicting the presence and production of atherosclerosis, an inflammatory
CAD.[1, 3, 6]
Kuller and associates[10] conducted a study that measured the relation between
CRP and subsequent risk of myocardial infarction (MI) and coronary heart disease
(CHD) with subjects who participated in the Multiple Risk Factor Intervention Trial
(MRFIT). They followed up with the participants up to 17 years for deaths and 6-7 years
for MIs. Upon follow-up, there were 98 MI cases and 148 CHD deaths. They found a
significant association between high CRP levels and subsequent CHD mortality. This is
the first prospective study to document the correlation between CRP and CHD mortality
in individuals with high CAD risk factors that were otherwise healthy.
JÃ¡noskuti and associates[11] conducted a study where they determined the risk of
mortality for an individual with high total cholesterol and low CRP levels compared to an

30
individual with low cholesterol and high CRP levels. The study found that patients with
high CRP and low total cholesterol have a higher risk for mortality than patients with low
CRP and high total cholesterol. This is a significant finding considering that for years it
has been emphasized that cholesterol is a primary risk factor determinant of CAD.
There have been many recent studies that have investigated the mechanisms of
how CRP contributes to the atherosclerotic process independently and through interaction
with other CAD risk factors. Aggregated CRP binds to LDL and very low density
lipoprotein (VLDL) which stimulates tissue factor production by macrophages and starts
coagulation. CRP has also been shown to mediate uptake of LDL into the macrophages
in the subendothelium. Smooth muscle cells and CRP are found to be in close apposition
with each other in the atherosclerotic process.[9] These mechanisms contribute to the
production of foam cells, which is a primary contributor to the formation of
atherosclerotic plaque. The MRFIT study found that only CRP and total cholesterol were
independent predictors of future cardiovascular risk.[10] However, they have also been
found to interact together in the formation of arterial plaque.[9] The oxidation of low
density lipoprotein (LDL) to foam cells is a continuous positive feedback inflammatory
response. As a result, production of CRP is mildly increased indicating that
atherosclerosis is taking place. CRP and cholesterol compliment each other in increasing
the risk of CAD.[12]
A meta-analysis of CRP concluded that it was the single most powerful predicator
of future CAD of all the inflammatory and lipid markers.[9] A study conducted with 437
patients that had unstable angina and non-Q-wave MI, showed that significantly
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increased CRP levels at the presentation of their cardiac episodes was a good predictor of
14-day mortality in that population.[13] Albert and associates[14] conducted a prospective
case-control study to determine the importance of CRP, homocysteine, and lipids as longterm predictors of sudden cardiac death. There were 97 cases of sudden cardiac death
among apparently healthy men examined. Baseline measures of CRP, homocysteine and
lipids were taken prior to their sudden cardiac death episode. Follow-up was carried out
over the next 17 years and determined that only baseline CRP levels were associated with
the risk of sudden cardiac death. The study’s conclusion suggests that CRP levels may be
useful in identifying apparently healthy men who are at an increased long-term risk of
sudden cardiac death. Thus, studying CRP levels as a determinant of CAD risk is a focus
in much of the literature.
Currently the clinical interventions to treat high CRP levels vary. Therapy
consists of one or a combination of the following interventions: medication, smoking
cessation, exercise, and weight loss. There is an abundance of literature that describes
how these factors affect CRP levels, but further studies are still needed.[9] Despite the
abundance of therapy interventions, it is unclear which are most effective in lowering
CRP levels.
Physical Activity
Physical activity has been studied as a potential treatment to reduce CRP levels.
Different results and conclusions have been made concerning the effects of exercise on
CRP levels. The discrepancies in the literature may be attributed to the type of exercise
intervention and its effects that are not directly related to CRP levels.
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Kelley and associates[15] examined the effects of aerobic exercise on CRP levels
in subjects that were older than 18 years of age. Their meta-analysis assessed
randomized controlled trials for 16 years. Measurements of CRP, body weight,
percentage of body fat, and maximum oxygen consumption were taken. The exercise
interventions lasted 4 weeks or more. Their methods included in the study were limited
to randomized controlled trials with aerobic exercise as the only intervention. Their
conclusion was that aerobic exercise does not reduce CRP levels in adults.
Marcell and associates[16] conducted a study to determine the effects of exercise
training on CRP levels. They also wanted to assess whether exercise-induced changes in
insulin resistance could be explained by changes in inflammatory markers, including
CRP. There were 51 participants who were middle-aged and overweight. Body fat and
CRP were measured before and after 16 weeks of moderate, intense or no exercise
training. They concluded that participation in moderate to intense exercise was not found
to be associated with improved CRP levels. Furthermore, they found exercise-induced
improvements in insulin sensitivity not related to CRP.
Other studies dispute the assertion that exercise itself does not reduce CRP levels.
Goldhammer and associates[17] examined the exercise effects on cytokines, a primary
stimulus for CRP production. They enrolled 28 CAD patients to participate in a 12-week
aerobic exercise program typical for cardiac rehabilitation programs. Participants were
required to train at 70-80% of their individual maximal heart rate. Training produced a
significant reduction of pro-inflammatory cytokines, including CRP levels. They
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concluded that aerobic exercise should be an effective means in reducing CRP levels
since pro-inflammatory cytokines are reduced with training.
Ford and associates[18] examined the association of physical activity and CRP
levels in a large national sample of the United States population. There were 13,748
participants who were 20 years of age or older enrolled in the study. The participants
were given the Third National Health and Nutrition Examination Survey between 1988
and 1994 and were asked questions regarding their physical activity in the past month
before taking the survey. Through the participants’ frequency and type of activity, four
levels of physical activity were defined: vigorously active, moderately active, lightly
active and sedentary. Blood was drawn after 10-16 hrs of fasting from each participant at
the session they attended and CRP levels were measured. After adjusting for
confounding variables, it was found that participants who engaged in light, moderate and
vigorous physical activity had lower CRP levels than participants who did not engage in
any physical activity. They concluded that physical activity reduces inflammation and
effectively lowers one’s CRP levels.
Williams and associates[19] examined the relationship between cardiorespiratory
fitness and CRP levels in early adulthood. The participants consisted of 400 men and 315
women all aged 26 years old. Measurements of their CRP levels, cardiorespiratory
fitness, anthropometric variables, and blood pressure were taken. The analysis controlled
for BMI and indicated that the participants' CRP levels are inversely associated with
cardiorespiratory fitness levels. This finding was independent of obesity, blood pressure,
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and smoking. The conclusion is that a reduction of inflammation (and CRP levels) due to
exercise may reduce the risk of CAD.
Plaisance and associates[20] reviewed the literature on the affects of weight loss
and exercise on CRP levels. Various cross-sectional and longitudinal studies indicate
that weight loss independently lowers CRP levels. However, the methods used in the
studies that concluded exercise does not independently lower CRP were insufficient
protocols for answering the question. Based upon studies with appropriate design and
methods, they conclude “exercise independently lowers CRP as much or more than
statins” (pg. 458). Thus, lifestyle intervention could be a very effective way of reducing
CRP levels. However, this conclusion is still controversial given the literature indicating
that exercise does not independently lower CRP.
Weight Loss
The literature supports the hypothesis that a reduction in adiposity is the primary
factor in exercise's efficiency in reducing CRP levels.[21-23] Florez and associates[21]
examined the correlation of CRP levels with waist circumference and BMI in people with
the metabolic syndrome (MS). They screened 190 participants for glucose intolerance
and BMI over 25. They did not include anyone with cardiac disease or that were taking
drugs that lower CRP. They then examined the relationship between CRP levels and MS
components and found abdominal obesity to be the most important component of MS that
was associated with high CRP levels.
Diaz and associates[22] evaluated the effect of weight and fitness on CRP levels.
They enrolled 2,112 adults from 20 to 49 years of age with a BMI greater that 18.5
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kg/m2. Fitness was determined by calculating the estimated maximal oxygen
consumption for each participant from submaximal graded exercise testing. Their
analyses indicated weight loss to be significantly and independently associated with
lower CRP levels regardless of their fitness level.
Reinehr and associates[23] compared the differences between the serum
concentrations of 14 non-obese children and 31 obese children. The obese children were
found to have significantly higher CRP levels than the non-obese children. They further
examined the changes in CRP levels in the 31 obese children. They observed that 16 of
the obese children lost weight and 15 obese children did not lose weight for one year.
The 15 obese children who did not lose weight had significantly higher serum CRP levels
than the 16 obese children who lost weight. They postulated that weight loss was
associated with a significant decrease in CRP levels.
Adipose tissue can add to the body’s expression of CRP. Anty and associates[24]
conducted a study with 46 severly obese individuals where 21 had MS and 25 did not.
Liver and adipose tissue biopsies were collected and used to determine the CRP gene
expression by real-time polymerase chain reaction. They found CRP levels to be
elevated in the severely obese individuals independent of the presence of MS. One
unique observation was that CRP gene expression was found in adipose tissue. Thus,
liver and adipose tissue could both contribute to high CRP levels in obese individuals.
This study leaves reason to assert that a lifestyle intervention to reduce adiposity could
contribute to lowering one’s CRP levels.
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Medications
Statins are drugs that lower the levels of LDL cholesterol and CRP.[25] A study
evaluated the relationships between the LDL cholesterol and CRP levels. There were
3745 patients with acute coronary syndromes that received statin therapy, which
consisted of 80 mg of atorvastatin or 40 mg of pravastatin per day, and were evaluated
for risk of recurrent MI or death from CAD. One of the key findings of the study was
that patients with lower CRP levels before receiving statin therapy had better clinical
outcomes than those with higher levels.[25] Statin therapy undoubtedly contributes to a
better clinical outcome for patients at risk for CAD, but additional research is necessary
to understand the independent effect of reducing CRP levels on CAD risk.
Ridker and associates[26] studied whether inflammation increases or decreases the
risk of thrombosis with asprin therapy. They randomly assigned 543 apparently healthy
men who had, developed within the eight years of the trial, myocardial infarction, stroke,
or development of venous thrombosis and 543 other apparently healthy men, who did not
develop CAD within the eight years, and treated each with asprin or placebo therapy.
Serum CRP levels were measured after the participants received their treatment. Their
conclusion states that asprin could prevent MI and ischemic stroke due to its antiinflammatory effects and reduction of CRP. However, the effects of asprin therapy are
relative to each individual. Therefore, CRP may serve as a suitable marker in identifying
the extent asprin reduces one’s inflammation.
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Confounding Variables
The literature on the effects of smoking on CRP levels is very interesting. The
research on smoking has delved into the frequency of smoking, the effects of tar, the
duration of being a smoker and other factors that may contribute to CRP levels.
CRP levels were measured in 400 men and women older than 65 years and free of
clinical CAD at baseline as part of the Cardiovascular Health Study. The association
between CRP levels and pack-years was found to be independent of the length of time
since cessation of smoking. That is, levels of CRP in these participants were elevated
and reflected their lifetime exposure to smoking independent of cessation.[27] CRP levels
were not reduced one year following smoking cessation.[28] Smoking did have
inflammatory effects on the body.[29] However, the literature supports the hypothesis that
elevated levels of CRP "are not directly attributable to tobacco use and are more likely to
be elevated due to a secondary process that is yet to be established" (pg. 865).[28]
The research on alcohol consumption indicates that it has a negative correlation
with CRP due to its anti-inflammatory effect. Stewart and associates[30] conducted a
study with 11,572 participants aged 17 and older to evaluate the association between
alcohol consumption and CRP levels. Using a model that adjusted for confounding
variables, they found that alcohol drinkers were less likely to have elevated CRP levels
than nondrinkers. They suggested moderate alcohol consumption might protect against
cardiovascular death.
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Diet
There are many studies that have examined the effects of dieting on CRP levels.
One diet in particular that has been studied is the Mediterranean diet. Michalsen and
associates[31] conducted a study where they examined the effects of the Mediterranean
diet on markers on inflammation, including CRP, in patients with CAD. A one-year
intervention of increased fish, fruits/vegetables and moderate canola/olive oil, the main
constituents of the Mediterranean diet, was consumed by 101 patients. The results
showed that adherence to the Mediterranean diet had no affect on CRP levels, indicating
that the diet had no affect on the metabolic and inflammation risks.
Chrysohoou and associates[32] explored the relationship between the
Mediterranean diet and CAD risk. They randomly enrolled 1514 men (18 to 87 years
old) and 1528 women (18 to 89 years old) from the Attica area of Greece, adherent to
Mediterranean diet. Contrary to Michalsen,[31] Chrysohoou found that adherence to the
traditional Mediterranean diet was associated with lower concentrations of biomarkers of
inflammation and coagulation, including CRP levels. They suggested that this may partly
explain the beneficial actions of this diet on the cardiovascular system.
Blum and associates[8] also determined explanations for reduced CAD risk when
one is adhering to the Mediterranean diet. They enrolled 80 healthy males and compared
levels of CRP when one consumes a Mediterranean-like meal compared to western-like
meal (high in saturated fat). They found that a postprandial Mediterranean meal
decreases CRP levels and concluded that these results provide a "potential explanation to
the protective properties of a Mediterranean diet against atherogenesis" (pg. 24). Thus,
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the literature is not consistent on the effects of adherence to the Mediterranean diet on
CRP levels.
The effects of other diets on CRP levels have also been studied. Bergesio and
associates[33] investigated the influence of the vegan diet supplemented with essential
amino acids (EAA) and ketoanalogues (VSD) on CRP levels. The Vegan diet is known
for its better lipoprotein profile and antioxidant vitamins content, which could protect
individuals against CAD. Bergesio enrolled 29 patients with advanced chronic renal
failure to be on a very low protein vegetarian diet and 31 patients with similar renal
function were enrolled on a conventional low-protein diet. The results indicated that the
patients on the vegan diet had lower CRP and LDL levels. They concluded that their
findings suggest that low-protein diets, and vegan in particular, may have a beneficial
effect reducing CAD risk for patients with renal disease Although this study was
conducted in a population with renal disease, the findings may support research to
determine the most efficient diet in lowering CRP levels.
Jenkins and associates[34] compared the efficacy of cholesterol lowering diets with
statins in lowering CRP levels. They enrolled 34 hyperlipidemic subjects who randomly
completed three one-month treatments of a very low-saturated fat diet (control), the same
diet with 20 mg lovastatin (statin), and a diet high in plant sterols, soy protein, viscous
fibers, and almonds. Fasting blood samples and measurements of total cholesterol and
CRP were obtained at weeks 0, 2, and 4. The results and conclusions indicated that a
combination of cholesterol-lowering foods reduced CRP levels similar to the extent of a
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statin drug. These findings indicate that dietary interventions can be just as effective as
drug therapy.
Huffman and associates[35] conducted a study with the objective of determining if
exercise training imposes change on CRP levels for men and women who are at risk for
cardiovascular disease. They took baseline and postintervention values of CRP for 193
sedentary individuals that were randomized to 1 of 3 groups that exercise with varying
intensities or a group assigned to be inactive for 6 months. They found cardiorespiratory
fitness to be inversely related to CRP levels independent of gender. However, they also
determined that the lack of a significant change in diet to accompany the exercise will not
significantly change CRP levels. Thus, diet may impact the effect exercise may have on
lowering CRP levels.
The combination of diet and exercise to reduce CRP is an area of research that
may help in developing a practical method of reducing the risk of cardiac events. The
CHIP program focuses on a diet and exercise intervention designed to reduce cardiac risk
factors. The data from these types of programs should contribute to our understanding of
the role of weight loss and exercise in reducing CRP levels.
Summary
CRP is an independent risk factor for CAD and can be used to predict future CAD
in an individual.[4, 5] The CHIP program is a lifestyle intervention program that uses diet
and exercise as a means to reduce CAD risk factors, thereby effectively reducing cardiac
episodes. Weight loss and exercise regimens adhered to by CHIP participants will be
examined and correlated with CRP levels. The results of this study will contribute to the
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literature in determining the independent and collective effects of exercise and weight
loss on CRP levels and help to design an efficient and practical intervention in reducing
CRP levels.
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Chapter 3
Methods
Subject Recruitment
The SwedishAmerican Center for Complementary Medicine (SACCM) recruited
the subjects for this study. Recruitment was from the Rockford, IL, metropolitan area
with the guidelines that all subjects be 18 years of age or older. All subjects provided
informed consent. Many subjects participated with a spouse or significant other. These
subjects were randomized as paired units while the other subjects were randomized as
individual units. Randomization of subject units was determined by a random number
generator. A study coordinator conducted the sign-up process for the program, subject
randomization, and subject group assignments. Subjects were excluded from the study if
they had a significant condition or major illness that would prevent them from exercising.
Total enrollment for the study was 366 randomly selected individuals with 180 in the
intervention group and 186 in the control group. Within the intervention group, 13 were
excluded due to illness unrelated to the study, unwillingness to commit to the CHIP
program and/or did not provide measurements after baseline, leaving 167 included in the
analysis. Within the control group, 16 were excluded due to illness unrelated to the
study, unwilling to commit to the CHIP program, lost interest and/or failed to complete
follow up measurements, leaving 170 to include in the analysis. The Institutional Review
Board of the SwedishAmerican Health System approved the study on August 29, 2002.
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Design
The study is a randomized control trial with a treatment group and a control group
that had measurements taken at baseline, six weeks, and six months. The treatment group
received their intervention in the first four weeks after baseline measurements. The
control group received no intervention and was specifically told not to alter their lifestyle
during the investigative period. They were also told that after six months they would be
able to participate in the CHIP program.
Intervention
The Coronary Health Improvement Project (CHIP)[36] served as the intervention
for this study. The program required the intervention group to meet and receive
instruction for two hours at each meeting. Instruction took place four times a week for
four weeks at the beginning of the study. The curriculum included the following topics:
modern medicine and health myths, atherosclerosis, coronary risk factors, obesity, dietary
fiber, dietary fat, diabetes, hypertension, cholesterol, exercise, osteoporosis, cancer,
lifestyle and health, the Optimal Diet, behavioral change, and self-worth.
The intervention group received a textbook and workbooks in conjunction with
the CHIP lectures that closely followed the discussion topics and contained assignments
with learning objectives that correlated with the discussion topics. These assignments
were designed to assist the intervention group in understanding and integrating the
concepts and information presented into their lives. Dieticians and medical professionals
introduced the intervention group to current nutritional and medical information that
related to the prevention of chronic diseases weekly.
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The intervention group was encouraged to follow pre-set dietary and exercise
goals. The dietary goal involved adopting the more plant-food based diet that emphasizes
"as-grown," unrefined food. The foods encouraged to eat were whole grains, legumes,
vegetables, and fresh fruits. The diet was low in fat, animal protein, sugar, salt, very low
in cholesterol, and high in fiber. The intervention group was also, accordingly with their
new diet, encouraged to progressively work toward walking or exercising at a mild-tomoderate intensity for at least 30 minutes a day. A pedometer was given to the
intervention group and they were encouraged to keep an exercise log that recorded the
miles they walked each day.
The primary objectives of this therapeutic lifestyle change program were to
improve the intervention group’s cognitive understanding of the importance of healthy
lifestyles, nutrition and physical activity behavior, risk factors associated with diabetes,
hypertension, cardiovascular disease, and cancer.
Measures
The variables gathered from the CHIP program to evaluate cardiovascular risk
factors and individual health variation were extensive. The CHIP variables used in the
proposed study are pedometer readings (strike counts), body weight, BMI, body fat
percentage, chronic inflammatory conditions, age, gender, and CRP levels. Baseline
values were taken for all participants and additional measurements were taken six weeks
and six months after the intervention group began the program.
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Physical Activity
To determine the level of physical activity, a 7-day self-recorded pedometer log
was maintained by each participant a week before measurements at baseline, six weeks,
and six months. Participants from the intervention and control group wore the Walk4Life
Model 2000 Life Stepper pedometer on a belt at the right hip directly above the right
knee cap each day for 7 consecutive days. Immediately prior to going to bed the
pedometer counts for the day were recorded and the number reset. Strike counts from
pedometers are a valid and reliable method of monitoring and measuring free-living
physical activity.[37-39] Crouter[37] determined the validity of the Walk4Life Life Stepper
pedometer by comparing pedometer readings with the number of actual steps of
participants walking for 5 min on a treadmill at various speeds (54, 67, 80, 94, and 107
m/min). The correlation coefficient was (r = 0.81, P<0.05) which Crouter indicates is
acceptable to ascertain physical activity and “a good choice to use in research.” Beets[38]
also assessed the Walk4Life pedometer by comparing it to actual steps from self-paced
walking and treadmill walking (speeds: 40, 54, 67, 80, and 94 m/min). The intraclass
correlation coefficient was (R = 0.997) for self-paced walking and (R = 0.516, 0.745,
0.946, 0.988 and 0.992) for treadmill speeds 40, 54, 67, 80, and 94 m/min respectively at
0.05 level of significance. Beets and Crouter both mention the Walk4Life pedometer to
be more accurate the faster one walks.
Tudor-Locke[39] conducted a study to determine how many days of pedometer
readings are needed to determine the weekly physical activity of an adult. There were 90
participants enrolled (33 men and 57 female aged 49 +/- 16.2 years and 44.8 +/- 16.9
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years respectively). BMI ranged from 21.1 to 33.9 kg/m2. There was an R2 of 0.94 and
an intraclass correlation of 0.80 for wearing the pedometer for three days. The
conclusion was that the time necessary to determine physical activity in a week with a
pedometer was 3 days. Thus, the time taken from this study (7 days) to determine
physical activity is sufficient.
CRP levels
Phlebotomists from the SwedishAmerican Health System's outpatient laboratory
drew blood using a vacutainer (Becton-Dickinson Vacutainer Systems, Rutherford, NJ)
after the participants had a 12-hour fast. Samples were allowed to clot and then
centrifuged. Clinical analyses were completed at the SwedishAmerican Health System
laboratory. CRP was determined using a microplate protocol based on a latex bead
enhanced immunoturbidity assay from the same technician and has been demonstrated to
be a valid and reliable method.[40-42] Otsuji[41] conducted a study that demonstrates a
turbidimetric immunoassay method for determining serum CRP that can be used with any
spectrophotometer that can measure turbidimetrically at 340 nm. The measured
absorbances of a test sample (50 μL of serum + 2.0 mL of working antiserum solution),
sample blank (50 μL of serum + 2.0 mL of sample blank buffer), reagent blank (50 μL
of saline + 2.0 mL of working antiserum solution), and buffer blank (50 μL of saline +
2.0 mL of sample blank buffer) were prepared and incubated at 37 °C for 30 min.
Absorbances for the test sample (AS), sample blank (ASB), the reagent blank (ARB), and
the buffer blank (ABB) were measured. The CRP absorbance (ACRP) indicating serum
CRP was calculated by the following equation: ACRP = AS – ASB – (ARB – ABB). It was
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indicated that precision was good due to low CV% and SD at various CRP
concentrations.
Rifai[42] compared latex-enhanced immunoassay for hs-CRP with Enzyme-Linked
ImmunoSorbent Assay (ELISA), a previously validated method for measuring hsCRP,[40] in a case controlled study using patients with peripheral arterial disease. There
were 288 subjects (144 case subjects and 144 control subjects) enrolled. The Latex assay
used monoclonal anti-CRP antibodies coated to polystyrene particles that formed a
complex with hs-CRP present in the measured study sample. The amount of scattered
light was directly proportional to the size of the antigen-antibody complex and reflected
the hs-CRP concentration present in the study sample. The run-to-run CVs, at hs-CRP
concentrations of 0.47, 10.5, and 54.9 mg/L were 6.4%, 3.7%, and 2.9%, respectively.
The correlation between the Latex and ELISA methods based on original and lognormalized data were (r = 0.95, P < 0.001) and (r = 0.93, P < 0.001) respectively for both
case and control groups. Thus, Rifai concluded that the Latex method was comparable to
ELISA and can be used in research to determine CRP levels.
Percent body fat
Percent body fat was estimated using the Tanita TBF - 300A electrical impedance
scale, which has been shown to be a valid and reliable method.[43, 44] Kyle[43] developed a
study to validate a single bioelectrical impedance analysis (BIA) equation for 343 healthy
white subjects (202 men and 141 women) aged 22-94 with a BMI between 17.0 and 33.8
kg/m. Fat-free mass (FFM) was measured by dual-energy x-ray absorptiometry (DEXA)
(Hologic QDR-4500) and BIA (Xitron 4000B). Significant correlations were high (r =
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0.986—0.987, P < 0.05), the standard error for the estimates was low (SEE = 1.72 kg),
and technical error was 1.74 kg. A valid single prediction for FFM was developed:
FFM = -4.104 + (0.518 x height(m)(2)/resistance (kg)) + (0.231 x weight (kg)) +
(0.130 x reactance (ohm)) + (4.229 x sex: men = 1, women = 0). He concluded that the
single prediction equation was valid for prediction of FFM in populations with large
variations of age and body composition.
Rubiano[44] investigated the validity of the leg-to-leg BIA (Tanita TBF 310) to
measure body composition using DEXA as a reference. He enrolled 39 subjects (8 male
and 31 female) aged from 37 to 73 years of age with a BMI from 24.6 to 32.6. A
significantly high correlation was observed (r = 0.94, P < 0.001, SEE = 3.58). Rubiano
concludes that leg-to-leg BIA systems may be useful in assessing total body composition
in a population varying in BMI.
Weight and height were measured using standard medical weight and height
scales calibrated by the Biometrics Department of the SwedishAmerican Health System.
Body mass index (BMI) was determined using the formula weight (kg)/height (m)2.
Presence of chronic conditions were determined by health history questionnaire
and documented by medical staff. Age and gender were also ascertained.
Statistical Analyses
Cross-tabulations will be used to perform bivariate analyses between intervention
status (intervention vs. control) and selected demographic variables and medication use,
with statistical significance based on the chi-square test for equal proportions (χ2).[45]
Repeated measures analysis of variance will be used to assess time and time by group
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effects on CRP level. Analyses were performed using SAS version 9.0 (SAS Institute
Inc., Cary, NC, USA, 2003). The polynomial option in the repeated statement will be
used with the SAS procedure statement GLM such that the transformation used to
implement the repeated measures analysis was an orthogonal polynomial transformation.
The spacing of the orthogonal polynomial used will reflect the time from baseline to six
weeks to six months. Wilks’ Lambda will be used to evaluate time and time by group
effects.[46] If the time effect is significantly different between groups, then the role of
physical activity, weight loss, smoking status, and alcohol consumption on explaining the
difference will be explored. The SAS procedure PROC FREQ will also be employed.
Statistical significance will be based on the 0.05 level.

50
References
1.

Sobal, G., Sinzinger, H., 2005. Effect of simvastatin on the oxidation of native
and modified lipoproteins. Biochemical Pharmacology. 70, 1185-1191.

2.

Petri, M., 2000. Detection of coronary artery disease and the role of traditional
risk factors in the Hopkins Lupus Cohort. Lupus. 9, 170-175.

3.

Backes, J.M., Howard, P.A., Moriarty, P.M., 2004. Role of C-reactive protein in
cardiovascular disease. The Annals Of Pharmacotherapy. 38, 110-118.

4.

Kasapis, C., Thompson, P.D., 2005. The effects of physical activity on serum Creactive protein and inflammatory markers: a systematic review. Journal Of The
American College Of Cardiology. 45, 1563-1569.

5.

Ledue, T.B., Rifai, N., 2003. Preanalytic and analytic sources of variations in Creactive protein measurement: implications for cardiovascular disease risk
assessment. Clinical Chemistry. 49, 1258-1271.

6.

Coppola, G., Corrado, E., Muratori, I., Tantillo, R., Vitale, G., Lo Coco, L., Novo,
S., 2006. Increased levels of C-reactive protein and fibrinogen influence the risk
of vascular events in patients with NIDDM. International Journal Of Cardiology.
106, 16-20.

7.

Caulin-Glaser, T., Falko, J., Hindman, L., La Londe, M., Snow, R., 2005. Cardiac
rehabilitation is associated with an improvement in C-reactive protein levels in
both men and women with cardiovascular disease. Journal Of Cardiopulmonary
Rehabilitation. 25, 332.

51
8.

Blum, S., Aviram, M., Ben-Amotz, A., Levy, Y., 2006. Effect of a Mediterranean
meal on postprandial carotenoids, paraoxonase activity and C-reactive protein
levels. Annals Of Nutrition & Metabolism. 50, 20-24.

9.

Li, J.-J., Fang, C.-H., 2004. C-reactive protein is not only an inflammatory marker
but also a direct cause of cardiovascular diseases. Medical Hypotheses. 62, 499506.

10.

Kuller, L.H., Tracy, R.P., Shaten, J., Meilahn, E.N., 1996. Relation of C-reactive
protein and coronary heart disease in the MRFIT nested case-control study.
Multiple Risk Factor Intervention Trial. American Journal Of Epidemiology. 144,
537-547.

11.

JÃ¡noskuti, L., FÃ¶rhÃ©cz, Z., HosszÃºfalusi, N., Kleiber, M., Walentin, S.,
BÃ¡lint, O., Duba, J., Rugonfalvi-Kiss, S., Romics, L., KarÃ¡di, I., FÃ¼st, G.,
ProhÃ¡szka, Z., 2005. High levels of C-reactive protein with low total cholesterol
concentrations additively predict all-cause mortality in patients with coronary
artery disease. European Journal Of Clinical Investigation. 35, 104-111.

12.

Agrawal, A., 2005. CRP after 2004. Molecular Immunology. 42, 927-930.

13.

Morrow, D.A., Rifai, N., Antman, E.M., Weiner, D.L., McCabe, C.H., Cannon,
C.P., Braunwald, E., 1998. C-reactive protein is a potent predictor of mortality
independently of and in combination with troponin T in acute coronary
syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.
Journal Of The American College Of Cardiology. 31, 1460-1465.

52
14.

Albert, C.M., Ma, J., Rifai, N., Stampfer, M.J., Ridker, P.M., 2002. Prospective
study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of
sudden cardiac death. Circulation. 105, 2595-2599.

15.

Kelley, G.A., Kelley, K.S., 2006. Effects of aerobic exercise on C-reactive
protein, body composition, and maximum oxygen consumption in adults: a metaanalysis of randomized controlled trials. Metabolism: Clinical And Experimental.
55, 1500-1507.

16.

Marcell, T.J., McAuley, K.A., TraustadÃ³ttir, T., Reaven, P.D., 2005. Exercise
training is not associated with improved levels of C-reactive protein or
adiponectin. Metabolism: Clinical And Experimental. 54, 533-541.

17.

Goldhammer, E., Tanchilevitch, A., Maor, I., Beniamini, Y., Rosenschein, U.,
Sagiv, M., 2005. Exercise training modulates cytokines activity in coronary heart
disease patients. International Journal Of Cardiology. 100, 93-99.

18.

Ford, E.S., 2002. Does exercise reduce inflammation? Physical activity and Creactive protein among U.S. adults. Epidemiology (Cambridge, Mass.). 13, 561568.

19.

Williams, M.J.A., Milne, B.J., Hancox, R.J., Poulton, R., 2005. C-reactive protein
and cardiorespiratory fitness in young adults. European Journal Of Cardiovascular
Prevention And Rehabilitation: Official Journal Of The European Society Of
Cardiology, Working Groups On Epidemiology & Prevention And Cardiac
Rehabilitation And Exercise Physiology. 12, 216-220.

53
20.

Plaisance, E.P., Grandjean, P.W., 2006. Physical activity and high-sensitivity Creactive protein. Sports Medicine (Auckland, N.Z.). 36, 443-458.

21.

Florez, H., Castillo-Florez, S., Mendez, A., Casanova-Romero, P., LarrealUrdaneta, C., Lee, D., Goldberg, R., 2006. C-reactive protein is elevated in obese
patients with the metabolic syndrome. Diabetes Research And Clinical Practice.
71, 92-100.

22.

Diaz, V.A., Player, M.S., Mainous, A.G., 3rd, Carek, P.J., Geesey, M.E., 2006.
Competing impact of excess weight versus cardiorespiratory fitness on
cardiovascular risk. The American Journal Of Cardiology. 98, 1468-1471.

23.

Reinehr, T., Stoffel-Wagner, B., Roth, C.L., Andler, W., 2005. High-sensitive Creactive protein, tumor necrosis factor alpha, and cardiovascular risk factors
before and after weight loss in obese children. Metabolism: Clinical And
Experimental. 54, 1155-1161.

24.

Anty, R., Bekri, S., Luciani, N., Saint-Paul, M.-C., Dahman, M., Iannelli, A.,
Amor, I.B., Staccini-Myx, A., Huet, P.-M., Gugenheim, J., Sadoul, J.-L., Le
Marchand-Brustel, Y., Tran, A., Gual, P., 2006. The inflammatory C-reactive
protein is increased in both liver and adipose tissue in severely obese patients
independently from metabolic syndrome, Type 2 diabetes, and NASH. The
American Journal Of Gastroenterology. 101, 1824-1833.

54
25.

Ridker, P.M., Cannon, C.P., Morrow, D., Rifai, N., Rose, L.M., McCabe, C.H.,
Pfeffer, M.A., Braunwald, E., 2005. C-reactive protein levels and outcomes after
statin therapy. The New England Journal Of Medicine. 352, 20-28.

26.

Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., 1997.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy
men. The New England Journal Of Medicine. 336, 973-979.

27.

Tracy, R.P., Psaty, B.M., Macy, E., Bovill, E.G., Cushman, M., Cornell, E.S.,
Kuller, L.H., 1997. Lifetime smoking exposure affects the association of Creactive protein with cardiovascular disease risk factors and subclinical disease in
healthy elderly subjects. Arteriosclerosis, Thrombosis, And Vascular Biology. 17,
2167-2176.

28.

Crook, M.A., Scott, D.A., Stapleton, J.A., Palmer, R.M., Wilson, R.F.,
Sutherland, G., 2000. Circulating concentrations of C-reactive protein and total
sialic acid in tobacco smokers remain unchanged following one year of validated
smoking cessation. European Journal Of Clinical Investigation. 30, 861-865.

29.

Wirtz, P.H., von KÃ¤nel, R., Kunz-Ebrecht, S., Ehlert, U., Fischer, J.E., 2004.
Enhanced glucocorticoid sensitivity of cytokine release from circulating
leukocytes stimulated with lipopolysaccharide in healthy male smokers. Brain,
Behavior, And Immunity. 18, 536-543.

55
30.

Stewart, S.H., Mainous, A.G., 3rd, Gilbert, G., 2002. Relation between alcohol
consumption and C-reactive protein levels in the adult US population. The Journal
Of The American Board Of Family Practice / American Board Of Family
Practice. 15, 437-442.

31.

Michalsen, A., Lehmann, N., Pithan, C., Knoblauch, N.T.M., Moebus, S.,
Kannenberg, F., Binder, L., Budde, T., Dobos, G.J., 2006. Mediterranean diet has
no effect on markers of inflammation and metabolic risk factors in patients with
coronary artery disease. European Journal Of Clinical Nutrition. 60, 478-485.

32.

Chrysohoou, C., Panagiotakos, D.B., Pitsavos, C., Das, U.N., Stefanadis, C.,
2004. Adherence to the Mediterranean diet attenuates inflammation and
coagulation process in healthy adults: The ATTICA Study. Journal Of The
American College Of Cardiology. 44, 152-158.

33.

Bergesio, F., Monzani, G., Guasparini, A., Ciuti, R., Gallucci, M., Cristofano, C.,
Castrignano, E., Cupisti, A., Barsotti, G., Marcucci, R., Abbate, R., Bandini, S.,
Gallo, M., Tosi, P.L., Salvadori, M., 2005. Cardiovascular risk factors in severe
chronic renal failure: the role of dietary treatment. Clinical Nephrology. 64, 103112.

34.

Jenkins, D.J.A., Kendall, C.W.C., Marchie, A., Faulkner, D.A., Josse, A.R.,
Wong, J.M.W., de Souza, R., Emam, A., Parker, T.L., Li, T.J., Josse, R.G., Leiter,
L.A., Singer, W., Connelly, P.W., 2005. Direct comparison of dietary portfolio vs
statin on C-reactive protein. European Journal Of Clinical Nutrition. 59, 851-860.

56
35.

Huffman, K.M., Samsa, G.P., Slentz, C.A., Duscha, B.D., Johnson, J.L., Bales,
C.W., Tanner, C.J., Houmard, J.A., Kraus, W.E., 2006. Response of highsensitivity C-reactive protein to exercise training in an at-risk population.
American Heart Journal. 152, 793-800.

36.

Diehl, H.A., 1998. Coronary risk reduction through intensive community-based
lifestyle intervention: the Coronary Health Improvement Project (CHIP)
experience. The American Journal Of Cardiology. 82, 83T-87t.

37.

Crouter, S.E., Schneider, P.L., Karabulut, M., Bassett, D.R., Jr., 2003. Validity of
10 electronic pedometers for measuring steps, distance, and energy cost. Medicine
And Science In Sports And Exercise. 35, 1455-1460.

38.

Beets, M.W., Patton, M.M., Edwards, S., 2005. The accuracy of pedometer steps
and time during walking in children. Medicine And Science In Sports And
Exercise. 37, 513-520.

39.

Tudor-Locke, C., Burkett, L., Reis, J.P., Ainsworth, B.E., Macera, C.A., Wilson,
D.K., 2005. How many days of pedometer monitoring predict weekly physical
activity in adults? Preventive Medicine. 40, 293-298.

40.

Wu, T.-L., Tsao, K.-C., Chang, C.P.Y., Li, C.-N., Sun, C.-F., Wu, J.T., 2002.
Development of ELISA on microplate for serum C-reactive protein and
establishment of age-dependent normal reference range. Clinica Chimica Acta;
International Journal Of Clinical Chemistry. 322, 163-168.

57
41.

Otsuji, S., Shibata, H., Umeda, M., 1982. Turbidimetric immunoassay of serum
C-reactive protein. Clinical Chemistry. 28, 2121-2124.

42.

Rifai, N., Tracy, R.P., Ridker, P.M., 1999. Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clinical Chemistry. 45, 2136-2141.

43.

Kyle, U.G., Genton, L., Karsegard, L., Slosman, D.O., Pichard, C., 2001. Single
prediction equation for bioelectrical impedance analysis in adults aged 20--94
years. Nutrition (Burbank, Los Angeles County, Calif.). 17, 248-253.

44.

Rubiano, F., NuÃ±ez, C., Heymsfield, S.B., 2000. A comparison of body
composition techniques. Annals Of The New York Academy Of Sciences. 904,
335-338.

45.

Fienberg, S. E., 1977. The analysis of cross-classified data. Cambridge, MA:
MIT Press, p. 9.

46.

Everitt BS, Dunn G., 1991. Applied multivariate data analysis. Edward Arnold,
London. Pp. 219-220

